- Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials
- Hydrochlorothiazide and alternative diuretics vs renin–angiotensin system inhibitors for the regression of left ventricular hypertrophy: A head-to-head meta-analysis
- DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine
- Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: A meta-analysis of observational studies
- Diminishing benefit of smoking cessation medications during the first year: A meta-analysis of randomized controlled trials
- Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers
- Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
- PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine vs intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder
- Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis
- Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders
- Prognostic impact of dna repair protein expression in non-small cell lung cancers treated with platinum-based chemotherapy and subsequent curative lung resection
- Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial
- Metformin's impact on statin-associated muscle symptoms: An analysis of ACCORD study data and research materials from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center
- Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis
- Randomised clinical trial: A leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease
Feed Sources
